109 related articles for article (PubMed ID: 15047202)
1. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.
Oelke M; Schneck JP
Clin Immunol; 2004 Mar; 110(3):243-51. PubMed ID: 15047202
[TBL] [Abstract][Full Text] [Related]
2. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.
Oelke M; Maus MV; Didiano D; June CH; Mackensen A; Schneck JP
Nat Med; 2003 May; 9(5):619-24. PubMed ID: 12704385
[TBL] [Abstract][Full Text] [Related]
4. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
Oelke M; Schneck JP
Immunol Res; 2010 Jul; 47(1-3):248-56. PubMed ID: 20087680
[TBL] [Abstract][Full Text] [Related]
5. HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma.
Jiang X; Lu X; Liu R; Zhang F; Zhao H
Clin Cancer Res; 2007 Dec; 13(24):7329-34. PubMed ID: 18094414
[TBL] [Abstract][Full Text] [Related]
6. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
Latouche JB; Sadelain M
Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520
[TBL] [Abstract][Full Text] [Related]
7. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
8. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL.
Chiu YL; Schneck JP; Oelke M
J Vis Exp; 2011 Apr; (50):. PubMed ID: 21505415
[TBL] [Abstract][Full Text] [Related]
9. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
[TBL] [Abstract][Full Text] [Related]
10. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
11. Quality and quantity: new strategies to improve immunotherapy of cancer.
Krueger C; Schneck JP; Oelke M
Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
[TBL] [Abstract][Full Text] [Related]
12. Use of immobilized HLA-A2:Ig dimeric proteins to determine the level of epitope-specific, HLA-restricted CD8(+) T-cell response.
Horowitz A; Li X; Poles MA; Tsuji M
Scand J Immunol; 2009 Nov; 70(5):415-22. PubMed ID: 19874545
[TBL] [Abstract][Full Text] [Related]
13. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
Hirano N; Butler MO; Xia Z; Berezovskaya A; Murray AP; Ansén S; Nadler LM
Clin Cancer Res; 2006 May; 12(10):2967-75. PubMed ID: 16707591
[TBL] [Abstract][Full Text] [Related]
14. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
15. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC).
Durai M; Krueger C; Ye Z; Cheng L; Mackensen A; Oelke M; Schneck JP
Cancer Immunol Immunother; 2009 Feb; 58(2):209-20. PubMed ID: 18563409
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting the presentation of exogenous hepatitis B virus core antigen.
Devasahayam M
Indian J Exp Biol; 2007 Aug; 45(8):689-95. PubMed ID: 17877145
[TBL] [Abstract][Full Text] [Related]
17. Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells.
Lu XL; Jiang XB; Liu RE; Zhang FC; Zhao HY
Cancer Lett; 2007 Oct; 256(1):128-35. PubMed ID: 17719173
[TBL] [Abstract][Full Text] [Related]
18. Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells.
Paine A; Oelke M; Blasczyk R; Eiz-Vesper B
Transfusion; 2007 Nov; 47(11):2143-52. PubMed ID: 17958544
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
Lu X; Jiang X; Liu R; Zhao H; Liang Z
Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
[TBL] [Abstract][Full Text] [Related]
20. Activated B cells mediate efficient expansion of rare antigen-specific T cells.
Zentz C; Wiesner M; Man S; Frankenberger B; Wollenberg B; Hillemanns P; Zeidler R; Hammerschmidt W; Moosmann A
Hum Immunol; 2007 Feb; 68(2):75-85. PubMed ID: 17321896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
